Après délibération, le collège de la Haute Autorité de santé, en sa séance du 17 décembre 2020 a constaté l’absence d’évaluation médico-économique du produit COREVALVE EVOLUT R & EVOLUT PRO sur les dépenses de l’assurance maladie.
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
4JPn944tTT3VhsAw
